These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 16489070)
1. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Collett K; Eide GE; Arnes J; Stefansson IM; Eide J; Braaten A; Aas T; Otte AP; Akslen LA Clin Cancer Res; 2006 Feb; 12(4):1168-74. PubMed ID: 16489070 [TBL] [Abstract][Full Text] [Related]
2. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673 [TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homologue 2 expression in breast carcinoma smears in relationship with p53, Ki-67 and other prognostic parameters. Athanassiadou AM; Tsipis A; Patsouris E; Gonidi M; Nicolopoulou-Stamati P; Chelidonis G; Athanassiadou P Acta Cytol; 2011; 55(2):180-6. PubMed ID: 21325804 [TBL] [Abstract][Full Text] [Related]
4. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. Choi JH; Song YS; Yoon JS; Song KW; Lee YY APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185 [TBL] [Abstract][Full Text] [Related]
5. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Ding L; Erdmann C; Chinnaiyan AM; Merajver SD; Kleer CG Cancer Res; 2006 Apr; 66(8):4095-9. PubMed ID: 16618729 [TBL] [Abstract][Full Text] [Related]
6. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Alford SH; Toy K; Merajver SD; Kleer CG Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Gonzalez ME; Li X; Toy K; DuPrie M; Ventura AC; Banerjee M; Ljungman M; Merajver SD; Kleer CG Oncogene; 2009 Feb; 28(6):843-53. PubMed ID: 19079346 [TBL] [Abstract][Full Text] [Related]
8. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features. Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. De Brot M; Rocha RM; Soares FA; Gobbi H Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210 [TBL] [Abstract][Full Text] [Related]
10. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757 [TBL] [Abstract][Full Text] [Related]
11. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors. Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903 [TBL] [Abstract][Full Text] [Related]
13. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627 [TBL] [Abstract][Full Text] [Related]
14. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895 [TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer. Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254 [TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer. Fang J; Zhang M; Li Q Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038 [TBL] [Abstract][Full Text] [Related]
17. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Dimri M; Bommi PV; Sahasrabuddhe AA; Khandekar JD; Dimri GP Carcinogenesis; 2010 Mar; 31(3):489-95. PubMed ID: 19969553 [TBL] [Abstract][Full Text] [Related]
18. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140 [TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration. Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997 [TBL] [Abstract][Full Text] [Related]
20. Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression. Pang J; Toy KA; Griffith KA; Awuah B; Quayson S; Newman LA; Kleer CG Breast Cancer Res Treat; 2012 Aug; 135(1):59-66. PubMed ID: 22527102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]